Global Atrial Fibrillation Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Atrial Fibrillation patients study in a new report ‘Global Atrial Fibrillation Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Atrial Fibrillation epidemiology, Atrial Fibrillation diagnosed patients, and Atrial Fibrillation treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Atrial Fibrillation derived from epidemiological analysis, percentage of patients diagnosed with Atrial Fibrillation, and percentage of patients treated with a therapy.
The study helps executives estimate Atrial Fibrillation market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Atrial Fibrillation prevalence, Atrial Fibrillation diagnosis rate, and Atrial Fibrillation treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.